DCs are potent APCs and key regulators of innate and adaptive immunity. After allo-SCT, their reconstitution in the peripheral blood (PB) to levels similar to those in healthy individuals tends to be slow. We investigate the age-and sex-dependant immune reconstitution of myeloid (mDC) and plasmacytoid DC (pDC) in the PB of 45 children with leukaemia or myelodysplastic syndrome (aged 1-17 years, median 10) after allo-SCT with regard to relapse, acute GVHD (aGVHD) and relapse-free survival. Low pDC/μL PB up to day 60 post SCT are associated with higher incidence of moderate or severe aGVHD (P = 0.035), whereas high pDC/μL PB up to day 60 are associated with higher risk of relapse (P o 0.001). The time-trend of DCs/μL PB for days 0-200 is a significant predictor of relapse-free survival for both mDCs (P o0.001) and pDCs (P = 0.020). Jointly modelling DC reconstitution and complications improves on these simple criteria. Compared with BM, PBSC transplants tend to show slower mDC/pDC reconstitution (P = 0.001, 0.031, respectively), but have no direct effect on relapse-free survival. These results suggest an important role for both mDCs and pDCs in the reconstituting immune system. The inclusion of mDCs and pDCs may improve existing models for complication prediction following allo-SCT.
INTRODUCTION
Allo-SCT is a potentially curative treatment option for certain haematological malignancies. [1] [2] [3] Relapse-free survival and GVHD severity have been linked to the speed of immune recovery as well as absolute cell counts in peripheral blood (PB) for various major immune subpopulations. 4 DCs are potent APCs that link and mediate the innate and the adaptive immune systems. [5] [6] [7] Although their importance in the healthy immune system and a variety of diseases is well established, their role in the reconstituting immune system after allo-SCT for leukaemia has not yet been fully elucidated, especially in children. Two main subtypes of DCs are present in PB: myeloid (mDCs) and plasmacytoid DCs (pDCs).
We and others established normal ranges for DCs in children showing significant differences in normal ranges by age. [8] [9] [10] [11] [12] For mDCs significant differences by sex were also found. 11 Thus, the use of age-(and sex-) dependant reference ranges is crucial when assessing the status of DCs in the PB of children.
After SCT, both mDC and pDC counts recover to pre-SCT levels within 2 months. 13 However, return to normal levels takes 1 year for mDCs and longer for pDCs. 13, 14 Previous publications found lower pDC 15 or both lower mDC and pDC 13, 14, 16 counts in the PB of patients with moderate to severe acute GVHD (aGVHD). However, others found no connection to aGVHD 17 or higher measurements in an early phase of aGVHD. 18, 19 These differing results may be partly explained by steroid application to treat aGVHD leading to a sharp decline of circulating pDCs. 19 Low DC counts at engraftment and after 3 months were associated with higher risk of relapse or lower EFS. [15] [16] [17] This study aims to assess the role of mDCs and pDCs in the reconstituting immune system of paediatric patients with leukaemia or myelodysplastic syndrome and their relevance for relapse, relapse-free survival and moderate to severe aGVHD. Very few publications linking survival to DC reconstitution after allo-SCT have considered that mDC and pDC normal values change with age and none have used age-and sex-dependant reference ranges to assess DC reconstitution in the PB.
The use of PBSC transplants in paediatric allo-SCT has been associated with higher mortality and a higher incidence of chronic GVHD (cGVHD). 13, 20, 21 Thus, the investigation of the role of PBSC vs BM transplants in DC reconstitution and complications will be a secondary objective.
PATIENTS AND METHODS

Patients and grafts
This study evaluates immune recovery, relapse-free survival and complications for 45 paediatric patients with leukaemia or myelodysplastic syndrome post allo-SCT (Table 1, Supplementary Table S1 ). In addition to routine monitoring of lymphocyte subsets, absolute mDC and pDC counts in PB were measured when blood was available.
Patients for whom at least five mDC and pDC measurements were available in the first 200 days were included in this study. All patients except one were monitored for at least 1 year after transplantation or until relapse or death. Median follow-up time for patients who did not experience relapse or death was 5 years.
This study was approved by the local ethics committee (Frankfurt, Germany). Treatment of patients was not affected by this study and no additional procedures were performed. Informed consent was obtained from all patients or their legal guardians.
Blood sample preparation and flow cytometric analyses Over the first 2 years after SCT, 1084 measurements (median of 20 per patient, range: 5-75) of absolute mDC and pDC counts in PB were collected. A median of 17 measurements were from the first 200 days. The antibodies, devices, gating strategy, quality control methods and method for the enumeration of rare events used for the flow cytometric enumeration of mDCs and pDCs were previously described.
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To summarise briefly, PB was collected into EDTA tubes and processed within 24 h in a lyse no-wash approach. We defined mDCs as CD45 23, 24 Absolute cell counts of mDCs and pDCs per μL PB were calculated using flow-count fluorospheres in a single-platform approach. Data were acquired for at least 300 s or 100 000 events for each sample, with higher minimum requirements of 420 s or 500 000 events used for some samples.
Immune reference ranges
Age-and sex-dependant mDC and pDC reference ranges were previously established from a data set of 100 healthy children 11 using the LMS method. 25 These reference ranges are used here to assess the immune reconstitution of the patients. This allows us to 'borrow strength' from exogenous information.
In a slight modification of Heinze et al.'s original approach, z-scores instead of percentiles are used to compare a patient's mDC or pDC counts with a healthy reference population (Figures 1a and b) , as z-scores measure large deviations more effectively. The z-score is the number of s.d. from the reference population median, allowing for age and possibly sex.
Unlike healthy individuals, patients post SCT may have (rounded) measurement values of 0 for mDCs or pDCs. To accommodate zeros in the Box-Cox transformation used in the creation of reference ranges, 1 is added to all measurement values, both for the 100 healthy individuals and the patients, as suggested by Box et al. 26 This does not affect the conclusions of this paper, but improves the numerical stability of the algorithms used.
Statistical analysis
Data analysis is performed using the R language and environment for statistical computing, version 3.01. 27 The survival package version 2. Normal mDC (a) and pDC (b) reference ranges for healthy individuals significantly depend on age. In the case of mDCs, they also significantly depend on sex (solid vs dashed lines). Shown are lines corresponding to the median (50th percentile), z-scores of ± 1 (~16-84th percentile corresponding to a 68% reference range) and z-scores of ± 2 (~2nd to 98th percentile corresponding to a 95% reference range).
The use of single measurements for statistical analysis is usually not recommended as the precise choice of time point may have an undue influence on the significance of the result. 32 Thus, summary measurements, such as the area under the curve (AUC, a type of weighted average) for short time intervals and the slope for longer trends, are recommended instead. 32 Early immune recovery is assessed using the AUC for days 0-60 and long-term recovery is investigated using the slope for days 0-200. Subsequently, joint modelling uses all available measurements.
Outcomes of interest are relapse-free survival, moderate to severe aGVHD (grade ⩾ II 33 ) and relapse. Onset of aGVHD was typically within the first 60 days after transplantation and systemic steroid application was the first line therapy for aGVHD grade ⩾ II. We had planned to include cGVHD as an outcome, but the study population contained too few (three) incidences of cGVHD.
Relationships between numerical and categorical variables are evaluated with the Kruskal-Wallis Rank Sum Test and Boxplots. Classification methods are assessed using false positive and true positive classifications. Occurrence of death or complications between two subgroups is compared using log-rank tests and Kaplan-Meier plots. The prognostic value of classification criteria is assessed using the explained variation for Cox proportional hazards models. 34 Joint modelling of time-to-event and immune reconstitution data produces predictive models and compensates for the possible influence of PBSC vs BM transplant source in immune reconstitution. 30, 35 A Cox proportional hazards model is used for the survival submodel. The longitudinal submodel includes patient level random effects for intercept and slope. Prospective accuracy of this model is assessed via timedependant AUC. 36 We use the Benjamini-Hochberg procedure to keep the false discovery rate for our eight key hypotheses (mDC/pDC AUC days 0-60 linked to relapse/aGVHD, mDC/pDC slope days 0-200 linked to relapse-free survival, mDC/pDC measurements in joint model linked to relapse-free survival) below 0.05. No hypotheses that would otherwise have been accepted are rejected because of the Benjamini-Hochberg procedure.
Corrected P-values are reported once in the text of the Results section, otherwise uncorrected P-values are given to facilitate comparison with other publications. For all conclusions presented, sensitivity analyses are performed to check whether the results depend on the precise choice of time points or patients. In addition, the effects of aGVHD grade ⩾ II, systemic steroid application, stem cell boosts, G-CSF application and donor characteristics on DC recovery and relapse-free survival are explored (see Supplementary Figures S2-S5, Supplementary  Tables S2-S6) .
RESULTS
Age-dependant reference ranges aid patient assessment Reference ranges for mDCs and pDCs for paediatric patients depend on age and, in the case of mDCs, sex. 11 Hence, measurements for two patients with similar absolute values may indicate a very different overall status of the immune system. Figure 2 shows two example patients with similar absolute pDC counts/μL PB. However, the first patient was a 2-year-old girl, whereas the second patient was a 8-year-old boy. Thus, their normal reference ranges and z-scores differ. The boy's pDC z-scores started low, he experienced aGVHD grade II, but he showed strong improvement in pDC counts over time and ultimately stayed in CR. The girl's pDC z-scores started high, she had aGVHD grade I, but only showed a small improvement in pDC counts and relapsed at day 342 post SCT.
Low pDC at days 0-60 associated with moderate to severe aGVHD To examine the association between moderate or severe aGVHD (grade ⩾ II) and early mDC/pDC reconstitution, the AUC (a weighted average) z-score summary measurements for days High pDC at days 0-60 associated with higher risk of relapse The pDCs z-score AUC for days 0-60 is linked to relapse at a later date (P o0.001, Benjamini-Hochberg corrected: P o 0.001, Figure 3b ), with higher early pDC z-scores associated with risk of relapse and lower early pDC z-scores associated with sustained remission. Almost all patients above z = − 2 (5/6) had a later relapse, whereas only one quarter (6/22) between z = − 3 and z = − 2 and none (0/8) below z = − 3 experienced this. This relationship similarly occurs for days 0-45 (P o0.001) and days 0 − 75 (P = 0.071). Again, the mDC z-score AUC from days 0-60 does not show a similar pattern (P = 0.284).
Successful DC reconstitution linked to relapse-free survival We assess long-term reconstitution using the slope of mDC/pDC zscores for days 0-200. Relapse-free survival is linked to both mDC (P o 0.001, Benjamini-Hochberg corrected: P o 0.001) and pDC (P = 0.020, Benjamini-Hochberg corrected: P = 0.032) reconstitution (Figures 3c and d) . Positive slopes are generally associated with relapse-free survival, whereas negative slopes are linked to death or relapse. Similar links are found for days 0-150 (mDC P = 0.002, pDC P = 0.008) and somewhat weaker links for days 0-100 (mDC P = 0.092, pDC P = 0.018). PBSC transplants seem to be associated with lower mDC and pDC slopes and, possibly, higher risk of relapse or death. This hypothesis will be further investigated using joint modelling below.
Segregation into high-risk and low-risk groups
To test the predictive performance of positive mDC or pDC z-score slopes for relapse-free survival and negative slopes for relapse or death, patients are segregated into two groups according to their mDC/pDC reconstitution from days 0-200. Patients with positive slopes are the 'low-risk' group, while patients with negative slopes are the 'high-risk' group. The Kaplan-Meier plots for relapse-free survival (Figure 4a and b) show a significant difference between the two groups both for mDCs (P o0.001) and for pDCs (P = 0.015).
For mDCs, this simple classification criterion correctly predicts 73% of patients who died or relapsed with a false positive rate of 18%. For pDCs, the true positive rate is 59%, whereas the false positive rate is 31%. In both cases, the slope from day 0-200 is a significantly better classifier than random with an area under the receiver-operator-curve of 0.852 for mDCs and 0.705 for pDCs (Supplementary Figure S1) . A Cox proportional hazards model for relapse-free survival with 'high-risk'/'low-risk' as the only predictor explains 25% of the variation in relapse-free survival time for mDCs and 27% for pDCs.
Predictive modelling for relapse-free survival The simple criteria for prediction of relapse-free survival in the previous section already perform significantly better than random. However, for use in clinical practise a more complex model is necessary that allows dynamic prediction at arbitrary time points. To achieve this, joint time-to-event and longitudinal models are fitted (Table 2) . For both mDCs (P o 0.001, Benjamini-Hochberg corrected: P o0.001) and pDCs (P o0.001, Benjamini-Hochberg corrected: P o 0.001) there is a significant link between immune reconstitution and the time to relapse or death. In both cases, higher mDC/pDC z-scores are associated with longer periods of relapse-free survival and increasing the z-score by 1 (for example, the difference between being in the 95% and 99.7% reference range) corresponds to an~50% reduction in the hazard of relapse or death.
For both mDCs and pDCs, there is a significant difference in immune reconstitution between BM and PBSC transplants. BM transplants show a significant increase with time for mDCs (approximately +1.2 z-score over 200 days, P = 0.016) and no significant reconstitution for pDCs (P = 0.583). In comparison, PBSC transplants show a negative slope for both mDC (approximately − 1 z-score over 200 days, P = 0.001) and pDC (approximately − 1 z-score over 200 days, P = 0.031) recovery. Importantly, no significant effect of PBSC/BM on relapse-free survival is found (P = 0.240, 0.525 respectively). This is because any effect of PBSC/ BM is on DC reconstitution and not directly on relapse-free survival. This model allows dynamic prediction of relapse-free survival based on the patient data available up to this point.
Using only the measurements up to day 100, the model achieves a time-dependant AUC of 0.68 (mDCs) and 0.67 (pDCs) for predicting relapse-free survival up to day 500. This improves on the simple distinction based solely on a positive or negative slope, as it allows for an earlier and dynamic prediction.
DISCUSSION
This study evaluated the immune reconstitution of mDCs and pDCs in children with leukaemia or myelodysplastic syndrome post allo-SCT with regard to aGVHD, relapse, and relapse-free survival. To gain statistical power, we 'borrowed strength' from our previously established age-and sex-dependant reference ranges and converted raw cell counts/μL PB to z-scores. So far, these ageand sex-dependant differences in normal DC values of healthy children have hampered the modelling of DC immune reconstitution in children post SCT. For this study, the creation of joint models without the use of z-scores was not possible due to insufficient power or due to numerical problems related to high variability of the measurements.
The association between both mDC and pDC reconstitution and relapse-free survival suggests an important role for both DC types in the reconstituting immune system. Like their role in the healthy immune system, they seem to mediate the GVL effect.
We found that high early pDC count is associated with increased risk of relapse, which may mirror the role of pDCs in autoimmunity in the healthy immune system. A possible explanation for this is that patients with more aggressive diseases (that is, early relapse) either experience accelerated pDC proliferation as a result of higher numbers of abnormal cells or that clinicians opted for a more aggressive transplant (that is, higher T cell counts or worse matching) to achieve an increased GVL effect. Furthermore, we found that higher mDC and pDC slopes over the first 200 days are associated with higher relapsefree survival. This is in line with what other authors have found for different time points. [15] [16] [17] Note that these two results are not contradictory-high initial pDCs over days 0-60 would lead to a limited scope for further expansion and therefore to a reduced slope over days 0-200.
Although the joint models were not meant for prediction and would require additional predictors to be useful for clinical practise, they already show great promise. Using only the measurements up to day 100, the models achieves a timedependant AUC of 0.68 for mDCs and 0.67 for pDCs for predicting relapse-free survival up to day 500. This is comparable with 0.70 . Kaplan-Meier plots with 95% confidence intervals of relapse-free survival over 500 days after transplantation. Patients are classified into a high-risk and a low-risk group depending on their mDC (a) or pDC (b) reconstitution over the first 200 days after transplantation. In each case, the group with successful reconstitution, that is, a positive slope of mDCs/pDCs z-scores over the first 200 days, exhibits significantly fewer incidences of relapse or death than the group with unsuccessful reconstitution, that is a negative z-score slope. for T cells and 0.62 for natural killer cells using preliminary joint models we generated for the raw measurements (data not shown). Therefore, we believe that for this limited study, the DC counts offer a similar amount of information about the current state of the patients as these populations, which are much bigger and arguably more immediately essential for survival. We intend to apply our reference percentile-based approach to T cells and natural killer cells in a future publication once age-and sexdependant reference percentiles compatible with our approach have been established for these populations. Our result that lower pDC count early post-SCT is associated with moderate to severe aGVHD was also found by previous studies. [13] [14] [15] [16] 37 This may be due to a delayed recovery of DCs for both aGVHD and cGVHD with the pDC subset being more affected. 13, 15, 16, 18, 19, 38 The reasons for lowered DC counts in PB may be complex as lowered counts were previously identified in individuals diagnosed with allergic diseases, autoimmune diseases or malignant diseases. 8, 9, [39] [40] [41] [42] However, high initial DC counts in the early phase of aGVHD followed by rapidly declining DC counts may be at least partly due to steroid application and other immunosuppressive therapies. 19, 43 Steroids influence DC recovery due to the downregulation of the costimulatory molecules present on the surface of immature DCs. 44 However, Vakkila et al.
14 found no change in DC recovery following steroid treatment. G-CSF, MTX or calcineurin inhibitors do not significantly impact DC recovery, 16, 18, 37 but there is evidence that immunosuppressive therapy interferes with DC function. 17, 38 Mycophenolate mofetil is detrimental to DC recovery with lower immature mDC counts 45 and also has an influence on other immune cells, for example, natural killer cells. 46 Lower pDC counts were observed after G-CSF mobilisation. 47 We found that PBSC transplants tended to start at higher initial DC levels and show a decline in both mDC and pDC measurements over time, whereas BM transplants tended to start at lower levels and showed an increase at least for mDCs. As this study was not designed to assess long-term DC reconstitution, we recommend further studies using regular measurements up to at least 1 year after SCT to investigate this further.
Various studies have identified differences in immune reconstitution for PBSC grafts compared with BM grafts: for PBSC, there is evidence of better initial DC reconstitution rates, 48 possibly owing to higher CD34 + cell content of the graft, 49 faster engraftment for either HLA-identical siblings or matched unrelated donor, 49, [50] [51] [52] [53] higher rates of relapse for HLA-identical siblings and matched unrelated donor, 49, 51, [54] [55] [56] and higher occurrence of both acute and chronic GVHD. 49, 51, [54] [55] [56] However, most studies find no difference between PBSC and BM grafts for HLA-identical siblings or matched unrelated donor in relation to aGVHD or cGVHD incidence, 48, 52, 53 non-relapse mortality, 50, 51 disease-free survival 50, 51, [54] [55] [56] and OS. 48, [50] [51] [52] [53] This study has some limitations: (i) small number of patients, (ii) small number of DCs circulating in PB, which may influence accuracy for DC measurements 57 and (iii) heterogeneity with regard to the underlying disease and the stem cell source. Accuracy may be improved by choosing markers with a better signal-to-noise ratio, for example, CD303 instead of CD123. 23 Differentiating between CD1c + and CD141 + mDCs in PB may provide insights into the functioning of these mDC subpopulations. 22 Chimerism analyses of DCs are highly relevant, but can be challenging in paediatric patients. Although for haploidentical transplants the analysis can be performed using flow cytometry and analysis of HLA type, 58 HLA-matched transplants require isolation of the DC subset in the blood and molecularbiological analyses, such as STR genotyping. 59 The volume of PB needed for the latter procedure is high due to the low abundance of DCs in PB and the purification level may be low. For this study, we were unable to collect the necessary PB for chimerism analyses due to ethical considerations. A previous study reported more than 95% donor chimerism for DCs before day 60 . 60 There appears to be no strong link between peripheral DC chimerism and relapse-free survival. 61 The literature differs on whether or not full DC chimerism is required for GVHD. 44, 61 The number of DCs/kg bodyweight contained in the graft may be a promising predictive factor for DC reconstitution and may explain some of the heterogeneity between patients. Regrettably, this information was not available for this study, so explicit modelling was not possible. However, in our joint model, the unobserved graft content (and any other observed variables) are accounted for by the random effects on intercept and slope of the DC reconstitution.
In summary, we presented, for the first time, an evaluation of age-and sex-dependant immune reconstitution in paediatric patients with leukaemia following allo-SCT. The predictive performance achieved in our study for aGVHD, relapse and relapse-free survival by using only mDCs or pDCs is significant, but too low for clinical practise. This suggests that additional information is needed to improve prediction. We have previously created uni-and multivariate predictive models for complications after allo-SCT based on larger immune subpopulations. 4, 62 These models may be improved by the incorporation of mDCs and pDCs as additional predictors. Ultimately, joint longitudinal and time-toevent models may provide dynamic complication prediction using multiple immune subpopulations.
Currently DC subpopulations are not usually included in the routine monitoring after SCT. Although the study population presented here is limited, our results suggest that DCs may be used to predict relapse-free survival and that inclusion in routine monitoring should be considered. As a next step, we recommend a larger scale study to create models that incorporate mDCs and pDCs as well as other immunological subpopulations. These models should take possible age-and sex-dependant changes in the normal reference ranges into account. Furthermore, we recommend chimerism analyses to determine what proportions of blood-circulating DCs are from donor and recipient at various time points. This may allow elucidation of the role of donor vs recipient DCs in GVL and graft-versus-host effects as well as DC recovery speed and the level of a homeostatic set-point for DCs.
